These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 19212674)

  • 1. Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing tyrosine kinase inhibitors in small cell lung cancer cells: implication of c-Src and its inhibitor.
    Ueda Y; Igishi T; Hashimoto K; Suyama H; Araki K; Sumikawa T; Takeda K; Nakazaki H; Matsunami K; Kodani M; Shigeoka Y; Matsumoto S; Shimizu E
    Int J Oncol; 2009 Mar; 34(3):689-96. PubMed ID: 19212674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing agents in K-ras mutation-harboring lung adenocarcinoma cells: implication of EGFR tyrosine kinase inhibitors.
    Ito S; Igishi T; Takata M; Ueda Y; Matsumoto S; Kodani M; Takeda K; Izumi H; Sakamoto T; Yamaguchi K; Makino H; Touge H; Chikumi H; Shimizu E
    Int J Oncol; 2014 Mar; 44(3):685-92. PubMed ID: 24399305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib mesylate (STI571) enhances amrubicin-induced cytotoxic activity through inhibition of the phosphatidylinositol 3-kinase/Akt pathway in small cell lung cancer cells.
    Suyama H; Igishi T; Ueda Y; Shigeoka Y; Kodani M; Morita M; Takeda K; Sumikawa T; Nakazaki H; Matsunami K; Matsumoto S; Shimizu E
    Oncol Rep; 2010 Jan; 23(1):217-22. PubMed ID: 19956885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
    Warshamana-Greene GS; Litz J; Buchdunger E; García-Echeverría C; Hofmann F; Krystal GW
    Clin Cancer Res; 2005 Feb; 11(4):1563-71. PubMed ID: 15746061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
    Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R
    Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin.
    Ceppi P; Papotti M; Monica V; Lo Iacono M; Saviozzi S; Pautasso M; Novello S; Mussino S; Bracco E; Volante M; Scagliotti GV
    Mol Cancer Ther; 2009 Nov; 8(11):3066-74. PubMed ID: 19861409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic Anti-Cancer Effects of AKT and SRC Inhibition in Human Pancreatic Cancer Cells.
    Ahn K; O YM; Ji YG; Cho HJ; Lee DH
    Yonsei Med J; 2018 Aug; 59(6):727-735. PubMed ID: 29978609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.
    Krystal GW; Honsawek S; Litz J; Buchdunger E
    Clin Cancer Res; 2000 Aug; 6(8):3319-26. PubMed ID: 10955819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
    Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways.
    Lai YH; Chen MH; Lin SY; Lin SY; Wong YH; Yu SL; Chen HW; Yang CH; Chang GC; Chen JJ
    Oncotarget; 2015 Sep; 6(28):26252-65. PubMed ID: 26312766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1.
    Krystal GW; DeBerry CS; Linnekin D; Litz J
    Cancer Res; 1998 Oct; 58(20):4660-6. PubMed ID: 9788619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential treatment with SN-38 followed by 5-fluorouracil shows synergistic cytotoxic activity in small cell lung cancer cells.
    Takeda K; Suyama H; Igishi T; Shigeoka Y; Matsumoto S; Yamasaki A; Hashimoto K; Sumikawa T; Morita M; Ueda Y; Shimizu E
    Oncol Rep; 2008 Apr; 19(4):945-51. PubMed ID: 18357380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells.
    Herynk MH; Beyer AR; Cui Y; Weiss H; Anderson E; Green TP; Fuqua SA
    Mol Cancer Ther; 2006 Dec; 5(12):3023-31. PubMed ID: 17172405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.
    Kopetz S; Lesslie DP; Dallas NA; Park SI; Johnson M; Parikh NU; Kim MP; Abbruzzese JL; Ellis LM; Chandra J; Gallick GE
    Cancer Res; 2009 May; 69(9):3842-9. PubMed ID: 19383922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
    Thibault B; Jean-Claude B
    J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.
    Phuchareon J; McCormick F; Eisele DW; Tetsu O
    Proc Natl Acad Sci U S A; 2015 Jul; 112(29):E3855-63. PubMed ID: 26150526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of akt/protein kinase B signaling by naltrindole in small cell lung cancer cells.
    Chen YL; Law PY; Loh HH
    Cancer Res; 2004 Dec; 64(23):8723-30. PubMed ID: 15574783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with the Chk1 inhibitor Gö6976 enhances cisplatin cytotoxicity in SCLC cells.
    Thompson R; Meuth M; Woll P; Zhu Y; Danson S
    Int J Oncol; 2012 Jan; 40(1):194-202. PubMed ID: 21894433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
    Formisano L; D'Amato V; Servetto A; Brillante S; Raimondo L; Di Mauro C; Marciano R; Orsini RC; Cosconati S; Randazzo A; Parsons SJ; Montuori N; Veneziani BM; De Placido S; Rosa R; Bianco R
    Oncotarget; 2015 Sep; 6(28):26090-103. PubMed ID: 26325669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells.
    Krystal GW; Honsawek S; Kiewlich D; Liang C; Vasile S; Sun L; McMahon G; Lipson KE
    Cancer Res; 2001 May; 61(9):3660-8. PubMed ID: 11325836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.